Transcriptional Link between Blood and Bone: the Stem Cell Leukemia Gene and Its +19 Stem Cell Enhancer Are Active in Bone Cells
John E. Pimanda(Cancer Institute of New South Wales), Anthony R. Green(Wellcome/MRC Cambridge Stem Cell Institute), Lev Silberstein(Massachusetts General Hospital), Asha Kallianpur(Cleveland Clinic Lerner College of Medicine), Massimo Dominici(University of Modena and Reggio Emilia), Scott Oldham(Wellcome Sanger Institute), Benjamin Dekel(Tel Aviv University), Mark E. Bowen(Stony Brook University), David Tannahill(Wellcome Sanger Institute), Stephen J. Brandt(Vanderbilt University Medical Center), Berthold Göttgens(Wellcome/MRC Cambridge Stem Cell Institute)
Cited by 18
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
<i>JAK2</i> Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
|New England Journal of Medicine|2007|1.2k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k